Member Info for digitalman

Actually who cares, what will be will be regarding placees. Today is a great day. Havent seen proper blue for ages.

A case could be made that you are implying with your questions, in direct response to my post, that I am trying to manipulate the sp?

Welshfalcon, do not call me a deramper for asking a question that has been on my mind and probably explains the complete disconnect currently between sp and true value. And more than anything else, being put into the same category as the weirdos is unnecessarily cruel.

Am I wrong in thinking that there are 60 million shares held by Al's 'city chums' who are waiting for anything ove 50 pence to unload and this will keep the sp in this range until such time as new significant investors come in and soak up this pile of cheap shares? He asks with steam coming out of ears, still.

30p twelve months ago. Now they have cash, (still have) FDA approval, huge partners and more sites up and running. Does seem very cheap at these levels even with recent dilution.

Why placing laplom? Could be partner?

@Rambo, I appreciate your analysis. It says to me they are running out of time to stop a low ball TO and in fact, may not be able to prevent it now. I only hope the offer is not insultingly low and the buyer is committed to providing chemo without side effects as fast as is possible.

Hey Rambo, fair comment, should have been more diligent in my search. Hes a TX man, he's there, got it.

The main point is, what has he been doing all this time? Are the ex-ceos comments in any way related to him and when are we going to see some results from his efforts? At £20k a month (i think someone mentioned this figure), there sure as sugar should be some tangible results on the way.

I wonder why Simon Bennett is not on the Group Team page on the Avacta site as CBO? Is this an odd omission? Also I wonder what he has achieved in the last nearly 5 months? This was what he said on 19th December 2023, 6 months ago;

“Avacta is at a pivotal point, having recently announced clinical data that have already begun to generate interest from potential commercial partners. I am delighted to be joining at such an exciting point in the journey of the business, to help the team optimise the commercial opportunities of their technologies and assets.”

Something has to be announced soon as all of this interest must have continued because the clinical results have continued to be excellent. The ex-ceo said 'smaller deals are easy' , was he blocking Bennett? Come on Avacta, its time to get motoring and bring this to market with a partner/partners asap.

Lots of upside here right now. Expect a busy time before results next Monday week.

Somethings cooking! Is it frying shorters?

They are already into phase 2 so 4 to 5 years to income seems very pessimistic along with 'strong doubts' about a buy out on stunning news. As they are targeting people who have exhausted all treatments and they are already showing strong indications, I would say great results will be classified as spectacular. Happy to be the optimistic view to your doom mongering.

Plenty of doom and gloom on offer today. Not long to see what the 20th May brings. Hopefuly spectacular data followed by a partnering announcement. Juho becomes the man of the hour!

21 out of last 25 posts green box rubbish for me. Very high level. Why are they so busy at the moment? They really are the most abnormal people unless they are being paid £10 a post or something, then they are simply mercenary. All day long, every day, on here trying to drag down a company's share value that ultimately wants to help sick people and their families. Relieved that I do not have to read a single word they say.

Oops, yes, I did mean Simon Bennett. Not been quite myself since the placing. :-)

What has the deal maker, Simon Brown, been doing for his £20k a month so far this year? Hopefully getting a deal ready to announce. And when that validation happens, this sp will be ancient history imo.

Sounds good to me. 20th May phase 2 data to be important for ongoing partnering discussions. Does this mean a licensing deal is actually close now depending on those results? Hope so.

That is his comparator deal for Avacta. J&J buying 'non commercial' stage Ambrx for $2 billion. £5 a share has been discussed?

Gosucki, you are one of them. pretending not to be. You are false. We are all celebrating and you are wondering about phase 3 failure. Pathetic.

Thanks for sharing